recombinant human serum albumin (rHSA), recombinant alpha-1 antitrypsin (rAAT), recombinant acidic fibroblast
growth factor (raFGF) and recombinant basic fibroblast growth factor (rbFGF).
Our study shows these plant-derived products are structurally and biochemically equivalent to or higher than those
in native form.
Innovation is the driving force behind Healthgen’s future growth supported by a strong Research & Development
(R&D) Pipeline.
Healthgen’s current pipeline programs comprise:
human serum albumin
human albumin
recombinant albumin
rHSA
recombinant HSA